What is the main action of leukotriene modifiers like Singulair?

Leukotriene modifiers, such as Singulair (montelukast), primarily act by reducing inflammation in the lungs. They work by blocking the action of leukotrienes, which are inflammatory mediators produced by the immune system. Leukotrienes contribute to inflammation, bronchoconstriction, and increased mucus production in conditions like asthma and allergic rhinitis. By inhibiting their effects, leukotriene modifiers help to decrease airway inflammation and improve overall respiratory function, making it easier for patients to breathe.

In the context of treating asthma, this reduction in inflammation is crucial, as it helps to prevent the worsening of symptoms and decreases the frequency of asthma attacks. The action of leukotriene modifiers is distinct from other classes of drugs used in asthma management, such as bronchodilators, which specifically target airway constriction by relaxing bronchial muscles.